ClinicaliQ Trial Snapshot
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia — Recruiting • Phase III • Oncology • NCT07277231.
- Treatment being tested: A fixed-duration combination of sonrotoclax (a novel BCL2 inhibitor) plus zanubrutinib (a Bruton tyrosine kinase inhibitor) compared to the established venetoclax plus acalabrutinib regimen in treatment-Phase IIIïve chronic lymphocytic leukaemia patients.
- Patient eligibility overview: Adults with previously untreated chronic lymphocytic leukaemia are eligible; specific age, performance status, and organ function criteria apply, with exclusions for prior CLL therapies and significant comorbidities.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Eligibility Snapshot
- : * Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment * Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 * Measurable disease by Computer Tomography/Magnetic Resonance Imaging * Adequate bone marrow and organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.